Psilocybin prevents chemotherapy nerve damage in preclinical study via mitochondrial protection

Chemotherapy saves lives. It also, in up to 60 percent of patients receiving certain regimens, leaves behind a particular kind of damage: sensory nerves in the hands and feet begin to fail. Numbness arrives first, then tingling, then pain so severe that doctors sometimes have to reduce doses or stop treatment altogether. This condition—chemotherapy-induced peripheral neuropathy, or CIPN—has resisted every preventive therapy developed so far. Patients manage the symptoms after they arrive. No one has stopped them from arriving in the first place.

A team of researchers has now traced, in mice and human nerve tissue, what happens at the cellular level when chemotherapy poisons these vulnerable nerves. The culprit is mitochondrial collapse. Cisplatin and similar drugs arrest the movement of mitochondria—the cell's energy factories—along the axons that extend from nerve bodies to fingertips and toes. Cut off from ATP, the energy currency that keeps them alive, the nerve endings starve. The damage compounds over repeated treatment cycles.

In a study published in Science, the researchers found that psilocybin, given before chemotherapy exposure, prevented or sharply reduced this cascade. In mouse models, two prophylactic doses of psilocybin completely blocked the mechanical hypersensitivity that normally follows cisplatin treatment. When the team extended the experiment across six monthly chemotherapy cycles—more than eight months of follow-up—cycle-matched psilocybin pretreatment sustained that protection. Critically, the drug did not measurably interfere with the tumor-fighting efficacy of the chemotherapy itself.

The mechanism turned out to depend on a specific serotonin receptor called 5-HT2A. When psilocybin activated this receptor, it triggered a molecular cascade that kept mitochondria moving along axons, preserving local energy supply to nerve endings even as cisplatin attacked. The researchers traced this pathway through multiple layers: they watched mitochondrial movement in live human nerve tissue harvested from surgical patients, they sequenced gene expression in human stem cell-derived sensory neurons, and they mapped the precise signaling molecules involved. The protection was real and reproducible.

Then came a finding that may reshape how this research moves forward. A non-hallucinogenic compound called TBG, which also activates the 5-HT2A receptor but does not produce psychedelic effects, provided protection against mechanical hypersensitivity comparable to psilocybin's. This suggests that the neuroprotective mechanism does not require the hallucinogenic activity at all—that the benefit comes from the receptor activation alone. For patients and clinicians, this opens a different path: a drug that prevents nerve damage without altering consciousness.

The study examined the problem from multiple angles. Researchers used behavioral tests to measure pain sensitivity, electrophysiology to track nerve firing patterns, and electron microscopy to visualize mitochondrial structure. They worked in mouse models of three different chemotherapy drugs—cisplatin, paclitaxel, and docetaxel—and in a syngeneic tumor model to ensure the protection held in a living cancer-bearing organism. They then validated key findings in human tissue: dorsal root ganglia from organ donors, peripheral nerves freshly harvested from 29 surgical patients, and lab-grown sensory neurons derived from human stem cells.

No preventive therapy for CIPN has ever been approved. Current treatment amounts to damage control after the fact. This research, still preclinical, suggests a preventive strategy: cycle-aligned 5-HT2A agonism, timed to protect nerves during each round of chemotherapy. The next step is clinical trials. The question is whether neuroprotection can be achieved in human patients without compromising the antitumor effect—and whether a non-hallucinogenic variant can deliver the same benefit that psilocybin showed in the lab.